I would add the MM space is very crowded but it was already crowded before. Abbott/Facet antibody looks very promising. This Onxy compound looked good. There's a next generation Revlimid that should be a lock. Beyond that I'm not sure there's much to get overly excited about in MM and nothing in small cap biotech that I'm aware of. imo.